Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates.
We infused somatostatin and its long-acting analogue (SMS 201-995) into the intracranial subarachnoid space of eight monkeys. Chronic infusions of SMS 201-995 produced marked neurotoxic effects characterized by truncal ataxia, dysmetria, and severe bradykinesia, with normal level of consciousness. Subcutaneous injection of apomorphine, a dopaminergic agonist, promptly reversed these effects. Further studies are required before intrathecal somatostatin replacement therapy can be offered to patients with Alzheimer's disease.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001786:Blood Glucose / Q000032:analysis; D002522:Chlorocebus aethiops; D007278:Injections, Spinal; D008297:Male; D009420:Nervous System / Q000187:drug effects*; D015282:Octreotide / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013004:Somatostatin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013997:Time Factors
D001786:Blood Glucose; D013004:Somatostatin; D001058:Apomorphine; D015282:Octreotide